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Abstract
Background: Glycine is known to protect against neuronal death. However, the underlying mechanism remains to
be elucidated. The microRNA-301a is involved in both biological and pathological processes. But it is not known
whether microRNA-301a has a neuroprotective property. In this study, we aimed to determine whether glycine-induced
neuroprotection requires microRNA-301a-dependent signaling.
Results: We provided the first evidence that glycine increased the expression of microRNA-301a in cultured rat cortical
neurons and protected against cortical neuronal death through up-regulation of microRNA-301a after oxygen-glucose
deprivation. MicroRNA-301a directly bound the predicted 3′UTR target sites of PTEN and reduced PTEN expression in
cortical neurons. We revealed that PTEN down-regulation by microRNA-301a mediated glycine-induced neuroprotective
effect following oxygen-glucose deprivation.
Conclusions: Our results suggest that 1) microRNA-301a is neuroprotective in oxygen-glucose deprivation-induced
neuronal injury; 2) glycine is an upstream regulator of microRNA-301a; 3) glycine confers neuroprotection through
microRNA-301a/PTEN signal pathway.
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Background
Glycine is the simplest non-essential amino acid, which
is a critical building block in many proteins. Glycine is
essential for the synthesis of many biomolecules such as
creatine, porphyrins and purine nucleotides. Glycine plays
a fundamental role in cell metabolism [1, 2]. In the adult
CNS, glycine is a major inhibitory neurotransmitter that
binds to glycine receptor (a chloride-permeable ion chan-
nel) to inhibit postsynaptic neurons [3–7]. Interestingly,
glycine is also a co-agonist of the excitatory NMDA recep-
tor, a calcium-permeable ion channel in the CNS [8, 9].
Glycine has been shown to have neuroprotective effect in
a variety of experimental models including ischemia–
reperfusion injury, anoxia, hypoxia, ROS, chemically in-
duced energy depletion [10–13]. In double-blinded,
placebo-controlled clinical trial, glycine treatment shows
significantly improved outcome and tended to decrease
the 30 day mortality of stroke patients [14]. However,
how glycine exerts its neuroprotective effect is largely
unknown.
The tumor suppressor PTEN (phosphatase and tensin
homolog deleted on chromosome 10) is a dual-
specificity phosphatase [15, 16]. PTEN is involved in the
regulation of several basic cellular functions, such as cell
cycle progression, cell migration, cell spreading and cell
growth [17]. We have previously shown that suppressing
PTEN confers neuroprotection [18]. Down-regulation of
PTEN is shown to protect against neuronal death
through the enhancement of Akt activation, the inhib-
ition of NR2B-containing NMDA receptors [18], the
preservation of GABAA receptors and the up-regulation
of TDP-43 [19, 20]. We have also shown that NR2A-
containing NMDA receptors and DJ-1 exert their neuro-
protective effects by down-regulating PTEN [20, 21].
Consistent with our findings, recent studies have re-
vealed that PTEN down-regulation is neuroprotective in
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cerebral ischemia, traumatic CNS injury and axon regen-
eration [22–36].
MicroRNAs (miRNAs) are a class of non-coding RNAs
(∼22 nucleotides) that negatively regulate protein expres-
sion [37, 38]. MiRNAs regulate the expression of at least
one third of the human genome and play a critical role
in a variety of normal biological processes including cell
differentiation, apoptosis, cell development and cell me-
tabolism [37, 39, 40]. In animals, miRNAs regulate
mRNA translation via imperfect pairing with nucleotide
sequences within the 3′-untranslated region (3′UTR) of
target genes [41].
MiRNA-301a (miR-301a) is the member of miR-130/
301a family. miR-301a has been shown to involve in some
biological and pathological processes, including cell devel-
opment, cell differentiation, inflammation, apoptosis and
cancer [42–45]. miR-301a is up-regulated in pancreatic
cancer and to activate NF-kB by negative regulation of
NF-kB-repressing factor gene [46]. miR-301a contributes
to IL-6-induced insulin resistance by direct regulation of
PTEN and downstream Akt signaling [47]. Recent studies
demonstrate that miR-301a promotes cancer cell metasta-
sis in breast, hepatocellular and gastric tumors through
different target genes [43, 44, 48]. However, it is not clear
whether miR-301a plays a role in neuronal survival.
In the present study, we demonstrate that glycine-
induced neuroprotection depends on miR-301a and its
downstream signaling. We show that the expression of
miR-301a is elevated by glycine. miR-301a mediates gly-
cine-induced neuroprotective effect in cultured cortical
neurons subjected to oxygen-glucose deprivation (OGD).
miR-301a binds the predicted 3′UTR target sites of PTEN
and reduces PTEN expression. We provide evidence that
glycine-induced neuroprotection is mediated through the
up-regulation of miR-301a and subsequent suppression of
PTEN expression.
Results
Glycine is neuroprotective in OGD-induced cortical neuronal
injury
Glycine has been shown to protect against OGD-induced
neuronal injury. To verify the neuroprotective role of
glycine in our experimental conditions, we examined the
effect of glycine on cultured cortical neurons subjected to
OGD. The cultured cortical neurons were injured by
OGD for 1 h. At 1 h after OGD insult the cortical neurons
were treated with glycine (100 μM). We treated the
neurons with glycine at 1 h after OGD, instead of be-
fore OGD, in this study because of its clinical rele-
vance. It is generally accepted that ischemic stroke
treatment is required to be done within 4.5 h after ischemia/
reperfusion onset. The treated neurons were collected
for cell death and viability assays at 24 h after OGD in-
sult. As shown in Fig. 1, LDH, MTT and FDA labeling
assays showed that treatment of glycine reduced OGD-
induced cortical neuronal death. These results support
Fig. 1 Glycine protects against OGD-induced cortical neuronal death. a, Glycine (10–300 μM) reduces OGD-induced increase of LDH release
(n = 6, *P < 0.05 vs. Sham; #P < 0.05 vs. Inj, ANOVA test). b, MTT assay shows that glycine (10–300 μM) increases neuronal survival rate in OGD-induced
cortical neuronal injury (n = 6, *P < 0.05 vs. Sham; #P < 0.05 vs. Inj, ANOVA test). c, Representative images of FDA labelling in cortical neuronal cultures
showing that glycine (100 μM) reduces OGD induced-neuronal death. Inj, injury; Gly, glycine
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a neuroprotective role of glycine in OGD-induced neur-
onal injury.
Glycine increases miR-301a expression in cortical neurons
To determine whether glycine exerts its neuroprotective
effect through regulating miRNA-dependent signaling, we
performed microarray to analyze the miRNA expression
profiles in cultured rat cortical neurons following glycine
treatment. The cultured neurons were treated with or
without glycine (100 μM) for 24 h and then collected for
miRNA microarray assays. Total RNAs were isolated from
glycine-treated cortical neurons and the miRNA micro-
array profiling of rat miRNA genes was performed
(Fig. 2a). We found that glycine treatment resulted in
differential changes in the expression of miRNAs in the
cortical neurons (Fig. 2a), among which the miR-301a
was markedly increased (Fig. 2b).
To provide further evidence to verify glycine-induced
increase of miR-301a, qRT-PCR was used to measure the
miR-301a expression after the rat cortical neurons were
treated with glycine (100 μM) for 24 h. As expected, the
qRT-PCR results confirmed that glycine enhanced the ex-
pression of miR-301a in the cortical neurons (Fig. 3).
miR-301a is neuroprotective in OGD-induced neuronal
injury
Given the neuroprotective effect of glycine, the observed
up-regulation of miR-301a by glycine led us to reason
that miR-301a may play a neuroprotective role in neur-
onal injury. We first set up to measure the response of
endogenous miR-301a to neuronal injury. We examined
the expression of miR-301a in cultured cortical neurons
at different time after OGD insult. The qRT-PCR data re-
vealed that the expression of miR-301a, but not miR-146a,
was decreased at 2, 6, 12 and 24 h after OGD-induced
injury in cultured cortical neurons (Fig. 4a, b).
To determine whether miR-301a is neuroprotective,
the cortical neurons were treated with miR-301a agomir
or agomir control. At 24 h after the treatment, the neu-
rons were subjected to OGD for 1 h. At 24 h after OGD
insult, we found that treatment of miR-301a agomir, but
not the agomir control, protected against OGD-induced
neuronal death after OGD insult (Fig. 4c). In the same
experimental protocols, treatment of miR-301a antagomir
but not antagomir control increased OGD-induced
neuronal death (Fig. 4d). These results provides the first
evidence that miR-301a is neuroprotective in neuronal
injury.
miR-301a is required for glycine-induced neuroprotection
To determine whether glycine-induced neuroprotection
is mediated through miR-301a, we first measured the ef-
fects of glycine on the expression of miR-301a in cul-
tured cortical neurons at different time following OGD
insult. The neurons were subjected to OGD for 1 h and
treated with glycine (100 μM) at 1 h after OGD. The
qRT-PCR data showed that glycine prevented OGD-
induced decrease of miR-301a at 2, 6, 12 and 24 h after
injury in cultured cortical neurons (Fig. 5a). To provide
evidence whether glycine-induced increase of miR-301a
conferred neuroprotection, the cortical neurons were
treated with miR-301a antagomir or antagomir control. At
24 h after treatment, the treated neurons were subjected
to OGD for 1 h. At 1 h after OGD injury the cortical neu-
rons were treated with glycine (100 μM) and collected for
cell death and viability assays at 24 h after OGD insult.
We showed that suppression of miR-301a by miR-301a
antagomir attenuated glycine-induced neuroprotective ef-
fect (Fig. 5b). To provide further evidence, we treated the
neurons with miR-301a agomir or agomir control. At 24 h
after the treatment, the neurons were subjected to OGD
for 1 h and then treated with glycine (100 μM). At 24 h
after OGD insult, we showed that the neuroprotective effi-
ciency induced by glycine in agomir-treated neurons was
not significantly higher than that in agomir control-
treated neurons (Fig. 5c), suggesting that miR-301a is in
the same pathway with glycine to exert neuroprotective ef-
fect. Collectively, these data indicate that glycine confers
neuroprotection through enhancing miR-301a expression.
PTEN is a target gene of miR-301a
To explore how miR-301a exerts its effect in mediating
glycine-induced neuroprotection, we analyzed the target
genes of miR-301a by miRanda (www.microrna.org),
TargetScan (www.targetscan.org) and miRDB (mirdb.org)
and predicted PTEN as a target of miR-301a. As shown in
Fig. 6a, miR-301a was predicted to target the 2206–2212
nts of PTEN 3′UTR. To determine whether miR-301a dir-
ectly binds the predicted 3′UTR sites of PTEN, we made
a reporter construct harbouring the 589 bp fragment of
PTEN 3′UTR flanking the entire putative target sequence.
We performed luciferase assay and showed that ectopic
expression of miR-301a agomir resulted in a significant re-
duction of luciferase activity in the PC12 cells (Fig. 6b).
The mutation of the seed sequence of miR-301a within
the 3′UTR of PTEN abrogated the inhibition of luciferase
activity by exogenous miR-301a agomir in PC12 cells
(Fig. 6b). In contrast, the luciferase activity was increased
in the PC12 cells co-transfected with a luciferase reporter
containing the PTEN-3′UTR (pMIR-PTEN 3′UTR) and
miR-301a antagomir (Fig. 6c). These results suggest that
miR-301a directly binds the predicted 3′UTR target sites
of PTEN.
PTEN is regulated by miR-301a in cortical neurons
To determine the functional consequence of miR-301a
binding to PTEN, we tested the effects of miR-301a ago-
mir or antagomir on the mRNA and protein expression
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Fig. 2 Glycine-induced increase of miR-301a expression in cortical neurons by microarray analysis. a, Heat map diagram showing differentially
expressed miRNAs in glycine (100 μM)-treated cortical neurons. The cortical neurons isolated from 3 rats were used for the assay. b, The data of
microarray assay show that the expression of miR-301a is remarkably increased in glycine (100 μM)-treated cortical neurons (n = 3, *P < 0.05 vs.
Control, ANOVA test). The levels of miR-301a detected by microarray were normalized to a negative control of U6 snRNA
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of PTEN in cortical neurons. We demonstrated that the
level of PTEN mRNA was down-regulated in the cul-
tured cortical neurons treated with miR-301a agomir for
24 h and up-regulated in the cultured cortical neurons
treated with miR-301a antagomir for 24 h (Fig.7a). West-
ern blot analysis further showed that 24 h treatment of
miR-301 agomir decreased the protein expression of
PTEN but 24 h treatment of miR-301 antagomir in-
creased the level of PTEN proteins in cultured cortical
neurons (Fig. 7b-c). These data indicate that miR-301
negatively regulates the mRNA and protein expression
of PTEN in cortical neurons.
miR-301a suppresses PTEN to mediate glycine-induced
neuroprotection
We next tested whether miR-301a mediates glycine-in-
duced neuroprotection through PTEN down-regulation.
The cultured cortical neurons were transduced with lenti-
viral vectors encoding PTEN cDNAs. At 48 h after trans-
duction, the neurons were subjected to OGD for 1 h. At
1 h after OGD injury the cortical neurons were treated
with glycine (100 μM) and collected for cell death and
viability assays at 24 h after OGD insult. We showed
that overexpression of PTEN reduced glycine-induced
neuroprotection (Fig. 8a).
The cortical neurons were also transduced with lenti-
viral PTEN siRNAs. At 48 h after transduction, the neu-
rons were subjected to OGD for 1 h. At 1 h after OGD
insult the neurons were treated with glycine (100 μM)
and collected for cell death and viability assays at 24 h
following OGD insult. We found that pre-suppression of
PTEN by the siRNA did not significantly enhance glycine-
induced neuroprotective effect (Fig. 8b).
The cortical neurons were then treated with lentiviral
PTEN siRNA or miR-301a antagomir. The neurons were
first treated with lentiviral PTEN siRNA. At 24 h
after the transduction, the neurons were treated with
miR-301a antagomir or antagomir control. At 24 h
after the treatment of antagomir or antagomir control, the
neurons were subjected to OGD for 1 h. At 1 h after
OGD insult the neurons were treated with glycine
(100 μM) and collected for cell death and viability assays
at 24 h after OGD insult. We demonstrated that PTEN
down-regulation by PTEN siRNA prevented miR-301a
antagomir from blocking glycine-induced neuroprotection
(Fig. 8c). Taken together, we conclude that miR-301a tar-
gets PTEN to mediate glycine-induced neuroprotection.
Discussion
Glycine is shown to confer protection against neuronal
injuries in both in vitro and in vivo experimental condi-
tions [10–13, 49, 50]. Importantly, clinical trial has shown
that glycine treatment improves outcome of ischemic
stroke patients [14]. However, how glycine exerts its neu-
roprotective effect remains to be elucidated. The present
study provides new evidence that the neuroprotective
effect of glycine is mediated by the enhancement of
miR-301a expression and subsequent suppression of
PTEN expression in cortical neurons. These findings re-
veal a molecular mechanism by which miRNA-dependent
signaling mediates glycine-induced neuroprotection. It is
not yet clear how miR301a is regulated by glycine. The
expression level of biologically active mature miRNAs
is the result of a fine mechanism of biogenesis, carried
out by different enzymatic complexes that exert their
function at transcriptional and post-transcriptional
levels [51]. It is possible that glycine may regulate the
processing of miRNA biogenesis. In the cytoplasm, Dicer
is an RNase III that digests the pre-miRNA into a 20–25
nucleotides mature duplex miRNA [51]. For example,
TAp63, a p53 family member, has been reported to co-
ordinately regulate Dicer and miR-130b to suppress
metastasis [52]. TAp63 binds to and transactivates the
Dicer promoter, resulting in a direct transcriptional regu-
lation of Dicer by TAp63 [52]. We would reason that
glycine may regulate miR301a through a transcriptional
mechanism by which Dicer is modulated. Further stud-
ies will be performed to test this hypothesis.
As glycine is a co-agonist of NMDA receptors, regula-
tion of miR301a by glycine may be mediated by NMDA
receptor-dependent signaling. Previous study has provided
evidence that the activation of GluN2A-containing NMDA
receptors, but not GluN2B-containing NMDA receptors,
contributes to glycine-induced neuroprotective effect in
ischemic injury [10, 50]. These studies show that glycine
induces its neuroprotection through enhancement of
Akt activation and CREB phosphorylation. Thus, it is ne-
cessary to investigate next whether GluN2A-containing
NMDA receptor-dependent Akt/forkhead/FOXO and/or
Fig. 3 Verification of glycine-induced increase of miR-301a by qRT-PCR.
qRT-PCR reveals that treatment of glycine (100 μM) for 24 h increased
the expression of miR-301a in cultured cortical neurons (n = 6, *P < 0.05
vs. Control, ANOVA test). The levels of miRNAs were calculated using U6
snRNA as an internal control
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CREB signaling mediate glycine-induced modulation of
miR-301a.
Recent studies indicate that miR-301a plays a critical
role in tumorigenesis [43, 44, 46, 48]. It has been re-
ported that miR-301a is up-regulated in hepatocellular
carcinoma and modulates NF-kB expression by negatively
regulating Gax [53]. miR-301a is also up-regulated in gas-
tric tumor cells and involved in the clinical progression
and prognosis of gastric cancer [45]. miR-301a promotes
migration and invasion by targeting TGFBR2 in human
colorectal cancer [48]. The up-regulation of miR-301a in
breast cancer and Ewing’s sarcoma cells promotes tumor
metastasis and tumor cell proliferation by targeting the
tumor suppressor PTEN [44, 54]. Through negative
regulation of SMAD4, miR-301a promotes pancreatic
cancer progression [55]. In addition to its effect on can-
cer, miR-301a is shown to play an important role in
regulating the expression of Kv4.2 in diabetes [56] and
controlling autoimmune demyelination by regulating
the T-helper 17 immune response [57]. Our study for
the first time demonstrates that miR-301a exerts a neu-
roprotective effect in OGD-induced neuronal injury,
implicating a therapeutic potential of miR-301a signaling
in neurological diseases. Interestingly, we reveal that
glycine acts as an upstream regulator to enhance miR-301a
expression, which confer neuroprotection in cortical
neurons.
We and others have previously revealed that down-
regulation of PTEN is neuroprotective in cerebral is-
chemia, traumatic CNS injury and axon regeneration
[16, 18, 20, 22–36]. We have shown for the first time that
depressing PTEN protects against ischemic neuronal
death through the enhancement of Akt activation, the in-
hibition of NR2B-containing NMDA receptors, and the
Fig. 4 miR-301a protects against OGD-induced cortical neuronal death. a, The expression of miR-301a in cultured cortical neurons at different time
following OGD insult are measured by qRT-PCR. miR-301a is decreased at 2, 6, 12 & 24 h after OGD insult (n = 3, *P < 0.05 vs. Sham, ANOVA test). The
data are normalized to that in Sham 1. b, The expression of miR-146a in cultured cortical neurons at different time following OGD insult are measured
by qRT-PCR. miR-146a is not altered at 2, 6, 12 & 24 h after OGD insult (n = 3, ANOVA test). The data are normalized to that in Sham 1. c, Treatment of
miR-301a agomir reduces OGD-induced cortical neuronal death. Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs. Inj, ANOVA
test). d, Treatment of miR-301a antagomir increases OGD-induced neuronal death. Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05
vs. Inj, ANOVA test). Inj, injury; Gly, glycine; Ant, antagomir; Ant-con, antagomir control; Ago, agomir; Ago-con, agomir control
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preservation of GABAA receptors [18, 19]. We also
show that PTEN suppression prevents excitotoxicity-
induced neuronal death via the up-regulation of nuclear
TDP-43 [20]. To understand how PTEN is regulated in
the neuronal injury process, we have revealed that
NR2A-containing NMDA receptors and DJ-1 act as the
negative regulators of PTEN to exert their neuroprotec-
tive effects [21]. In the present study, we provide new
evidence that PTEN is negatively regulated by miR-301a
and that PTEN suppression by miR-301a up-regulation
mediates glycine-induced neuroprotective effect. Thus, we
identify a molecular mechanism by which the glycine/
miR-301a signal pathway negatively regulates PTEN in
conferring neuroprotection.
Methods
Neuronal culture and OGD insult
The cortical neuronal cultures were prepared from
Sprague–Dawley rats at gestation day 17 as described
[58, 59]. Briefly, dissociated neurons were suspended in
plating medium (Neurobasal medium, 2 % B-27 supple-
ment, 0.5 % FBS, 0.5 μM L-glutamine, and 25 μM glutamic
acid) and plated on poly-D-lysine coated Petri dishes. After
1 day in culture, half of the plating medium was removed
and replaced with maintenance medium (Neurobasal
medium, 2 % B-27 supplement, and 0.5 μM L-glutamine).
Thereafter, maintenance medium was changed in the
same manner every 3 days. The cultured neurons were
used for experiments at 12 days after plating.
Fig. 5 miR-301a mediates glycine-induced neuroprotective effect. a, Glycine treatment increases miR-301a expression after OGD (n = 3, *P < 0.05
vs. Sham, #P < 0.05 vs. Inj, ANOVA test). b, Treatment of miR-301a antagomir, but not antagomir control, attenuates glycine-induced neuroprotection
against LDH release in cultured cortical neurons subjected to OGD insult. Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs. Inj,
**P < 0.05 vs. Inj + Gly, ANOVA test). c, Treatment of miR-301a agomir in cultured cortical neurons does not enhance glycine-induced neuroprotective
effect after OGD insult. Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs. Inj + Gly, ANOVA test). Inj, injury; Gly, glycine;
Ant, antagomir; Ant-con, antagomir control; Ago, agomir; Ago-con, agomir control
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To initiate the OGD challenge, cells were transferred
to deoxygenated glucose-free extracellular solution (ECS)
(in mM: 116 NaCl, 5.4 KCl, 0.8 MgSO4, 1.0 NaH2PO4, 1.8
CaCl2, and 26 NaHCO3), introduced into a specialized
chamber (Plas-Labs, Lansing, MI), and maintained at 37 °C
in 85 % N2/10 % H2/5 % CO2 for 1 h. Neurons were re-
moved from the chamber, transferred to maintenance
medium, and returned to the incubator. For “sham”
Fig. 6 miR-301a directly binds the predicted 3′UTR target sites of
PTEN. a, The predicted miR-301a target sequence in the 3′UTR target
sites of the PTEN gene. A mutation was generated in the seed region
of PTEN 3′UTR as indicated by the underline. b, Luciferase reporter
assays in PC12 cells transfected with pMIR-REPORT Luciferase vector
carrying PTEN 3′UTR (PTEN wild-type) versus pMIR-mut-PTEN 3′UTR
(PTEN mutant) in the absence or presence of miR-301a agomir. The
luciferase activity was reduced in the PC12 cells co-transfected
with a luciferase reporter containing the PTEN 3′UTR and miR-301a
agomir (n = 6, *P < 0.05 vs. miR-301a agomir control, ANOVA test).
C, Luciferase reporter assays in PC12 cells transfected with pMIR-REPORT
Luciferase vector carrying PTEN 3′UTR (PTEN wild-type) versus
pMIR-mut-PTEN 3′UTR (PTEN mutant) in the absence or presence
of the miR-301a antagomir. The luciferase activity was increased in
the PC12 cells co-transfected with a luciferase reporter containing
the pMIR-PTEN 3′UTR and miR-301a antagomir (n = 6, *P < 0.05 vs.
miR-301a antagomir control, ANOVA test). Control: untransfected
PC12 cells; Blank: PC12 cells transfected with pMIR-REPORT Luciferase
vector carrying PTEN wild-type or PTEN mutant without miR-301a
agomir or antagomir
Fig. 7 miR-301a regulates PTEN expression. a, qRT-PCR shows that
the levels of PTEN mRNAs are down-regulated and up-regulated in
the cortical neurons treated with miR-301a agomir and antagomir,
respectively (n = 6, *P < 0.05 vs. agomir control, #P < 0.05 vs. antagomir
control, Student t test). b, Western blot assay shows that the levels of
PTEN proteins in the cortical neurons treated with miR-301a agomir
are reduced (n = 6, *P < 0.05 vs. agomir control, ANOVA test).
c, Western blot assay shows that the levels of PTEN proteins in the
cortical neurons treated with miR-301a antagomir are increased
(n = 6, *P < 0.05 vs. antagomir control, ANOVA test)
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treatment, cultures were transferred to the ECS (in mM:
116 NaCl, 5.4 KCl, 0.8 MgSO4, 1.0 NaH2PO4, 1.8 CaCl2,
26 NaHCO3, and 33 glucose), introduced into the cham-
ber, and maintained at 37 °C for 1 h in 95 % O2/5 % CO2.
After the sham treatment, the neurons were transferred to
maintenance medium and returned to the original
incubator.
LDH Assay
The lactate dehydrogenase (LDH) is a cytoplasmic enzyme
retained by viable cells with intact plasma membranes and
released from cells with damaged membranes. The LDH
release was measured using CytoTox 96 Cytotoxicity kit
based on the manufacturer’s instructions (Promega, USA).
The levels of maximal LDH release were measured by
Fig. 8 miR-301a mediates glycine-induced neuroprotection through suppression of PTEN. a, Transfection of PTEN cDNA reduces glycine-induced
neuroprotection in cultured cortical neurons subjected to OGD insult. Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs.
Inj, **P < 0.05 vs. Inj + Gly, ANOVA test). b, Suppression of PTEN by PTEN siRNA in cultured cortical neurons does not increase glycine-induced
neuroprotective effect in OGD insult (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs. Inj, ANOVA test). Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05
vs. Sham, #P < 0.05 vs. Inj, ANOVA test). c, PTEN siRNA treatment prevents miR-301a antagomir from blocking glycine-induced neuroprotection.
Left, LDH assay; Right, MTT assay (n = 6, *P < 0.05 vs. Sham, #P < 0.05 vs. Inj, **P < 0.05 vs. Inj + Gly, ##P < 0.05 vs. Ant + Inj + Gly, ANOVA test). Inj,
injury; Gly, glycine; Ant, antagomir; Ant-con, antagomir control; Ago, agomir; Ago-con, agomir control; PT-cDNA, PTEN cDNA; PT-siR, PTEN siRNA
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treating the cultures with 10× lysis solution (provided by
the manufacturer) to yield complete lysis of the cells.
Absorbance data were obtained using a 96-well plate
reader (Molecular Devices, USA) at 490 nm. According
to the manufacturer’s instructions, the LDH release (%)
was calculated by calculating the ratio of experimental
LDH release to maximal LDH release.
MTT Assay
The viability of the cells in the neuronal cultures was
assessed by their ability to uptake thiazolyl blue tetrazo-
lium bromide (MTT). The cells were incubated with
MTT for 1 h, then lysed with dimethyl sulfoxide (DMSO)
and left at room temperature in the dark overnight. The
lysates were then read on a plate reader (PowerWave X,
Bio-Tek) at the absorbance wavelength of 540 nm.
Labeling of cortical neurons by fluorescein diacetate
Fluorescein diacetate (FDA) was performed to detect
neuronal viability. Briefly, cultures were rinsed with extra-
cellular solution and incubated with FDA (5 μM) for
30 min. The cultures were washed with extracellular
solution and then viewed on an Olympus fluorescent
microscope (IX51, Olympus).
miRNA microarray assay
Cultured rat cortical neurons treated with or without
glycine (100 μM) for 24 h were collected for miRNA
microarray analysis. Total RNAs were isolated using
TRIzol reagent (Invitrogen, USA) and a miRNeasy Mini
Kit (QIAGEN, Germany). RNA samples were applied to
the miScript miRNA PCR Arrays (QIAGEN, Germany).
Expression profiling was done with dissociation curves
using ABI QuantStudio 6 K Flex (ABI, USA). 500 ng
RNA template, miScript Reverse Transcriptase Mix
(2 μl), 5× miScript HiSpec Buffer (4 μl), 10× miScript
Nucleics Mix (2 μl) added into RNase-free water to the
volume of 20 μl. Reverse transcription reactions were in-
cubated at 37 °C (60 min) followed by at 95 °C (5 min).
The qPCR reactions were consisted of cDNA template
(0.8 μl), 2× QuantiTect SYBR Green PCR Master Mix
(12.5 μl), 10× miScript Universal Primer (2.5 μl), added
into RNase-free water to the volume of 25 μl. Reactions
were incubated at 95 °C (15 min), followed by 40 cycles
at 94 °C (15 s), 55 °C (30 s) and 70 °C (30 s), followed by
melting curve ananlysis. Fold changes in miRNA expres-
sion were calculated using the comparative Ct method
and normalized to U6 small nuclear RNA (snRNA) as
endogenous control. After normalization, differentially
expressed miRNAs were identified through Fold Change
filtering.
Real-time qRT-PCR
For the quantification of miRNAs or mRNA, total RNAs
were isolated using TRIzol reagent (Invitrogen, USA),
the reverse transcribed using Maxima H Minus First
Strand cDNA Synthesis Kit (Thermo, USA) and the qPCR
reaction using SYBR Green qPCR Master mixture (ABI,
USA). The reverse transcription was performed on Bio-
Rad MJ Mini Instrument (Bio-Rad, USA) and qPCR
was performed on QuantStudio 6 K Flex Instrument
(ABI, USA).
For the quantification of miRNAs, 2 μg RNA template
and 500 nM RT Primer (2 μl) added into RNase-free
water to the volume of 11 μl, were incubated at 70 °C
(10 min) followed by on ice (2 min), then 5× RT Buffer
(5 μl), 2.5 mM dNTP Mix (2 μl), 100U RT enzyme (1 μl)
added into RNase-free water to the volume of 25 μl. Re-
verse transcription reactions were incubated at 42 °C
(60 min) followed by at 70 °C (10 min). The miRNA qPCR
reactions were consisted of SYBR Green qPCR Master
mixture (10 μl), cDNA template (2 μl), 5 μM Bulge-Loop
miRNA Forward Primer (0.8 μl) and 5 μM Bulge-Loop
miRNA Reverse Primer (0.8 μl) added into RNase-free
water to the volume of 20 μl. Reactions were incubated at
95 °C (20 s), followed by 40 cycles at 95 °C (10 s), 60 °C
(20 s) and 70 °C (10 s), followed by melting curve analysis.
For the quantification of mRNA, 2 μg RNA template,
25 pM oligo (dT) Primer (0. 25 μl), 10 mM dNTP Mix
(1 μl), 5× RT Buffer (4 μl), Maxima H Minus Enzyme
Mix (1 μl) were added into RNase-free water to the
volume of 20 μl. Reverse transcription reactions were
incubated at 25 °C (10 min) followed by at 50 °C
(15 min) and at 85 °C (5 min). The qPCR reaction mix-
tures included the SYBR Green qPCR Master mixture
(10 μl), cDNA template (2 μl) and 10 μM Forward Pri-
mer (0.6 μl) and 10 μM Reverse Primer (0.6 μl) added
into RNase-free water to the volume of 20 μl. Reactions
were incubated at 95 °C (3 min), followed by 40 cycles at
95 °C (10 s), 60 °C (30 s), followed by melting curve ana-
lysis. All reactions were performed in triplicate for each
sample tested. The median Ct (Cycle threshold) value was
used for analysis. Relative quantities were calculated using
the 2-△△Ct method with U6 snRNA/β-actin. Three inde-
pendent experiments were performed.
Constructs and treatment
The miR-301a agomir, agomir control, antagomir, antago-
mir control were purchased from RioBio (China). The cul-
tures were washed with ECS for 10 min, and then treated
with serum-free medium supplemented with 1.0 μM
agomir, agomir control, antagomir or antagomir control
for 2 h at 5 % CO2, 95 % humidity and 37 °C. After incu-
bation, the cultures were further cultured in maintenance
medium for 24 h [60].
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The lentiviral PTEN cDNA particles and lentiviral
PTEN siRNA particles were purchased from GeneChem
(China). The treatment of particles was performed in
cultured cortical neurons based on the manufacturer’s
instructions.
Luciferase assay
A 589 bp fragment of the PTEN mRNA-3′UTR was amp-
lified from cDNA by PCR and cloned into pMIR-REPORT
Luciferase vector (Invitrogen, USA) to make pMIR-PTEN-
3′UTR reporter construct. The primes were 5′-GGAC
TAGT GGATTTACACATTTATATTTGAACA-3′(F) and
5′-CCCAAGCTT TACCTACAGAACGCAGTTCAGGC
TA-3′(R). Site-directed mutagenesis was performed to dis-
rupt the sequence within PTEN mRNA-3′UTR which was
complementary to the miR-301a (MIMAT0000552) seed
region, and the primers were purchased from RioBio
(China). The mutated vector was named pMIR-mut-PTEN
3′UTR. The reporter constructs were confirmed by DNA
sequencing.
A total of 5 × 104 PC12 cells were seeded in 24-well
plates for 24 h and then co-transfected with 100 ng
pMIR-PTEN-3′UTR constructs using Lipofectamine
2000 (Invitrogen, USA) with 1.0 μM miR-301a agomir
or agomir control, or with the miR-301a antagomir or
antagomir control. Renilla luciferase pRL-TK reporter
(Promega, USA) was co-transfected to monitor the
transfection efficiency. At 24 h post-transfection, the lu-
ciferase activities were measured by the dual-luciferase re-
porter assay system using the Glomax2020 luminometer
(Promega, USA). Data were normalized by Renilla lucifer-
ase. Each experiment was performed at least three times
in triplicate wells.
Western blotting
Western blotting assay was performed as described pre-
viously [18, 58]. For the detection of phospho-Akt, the
samples prepared in the same day were used. The poly-
vinylidene difluoride membrane (Millipore, USA) was
incubated with primary antibody against PTEN and β-
actin (Cell Signaling, USA). Primary antibodies were
labeled with horseradish peroxidase-conjugated secondary
antibody, and protein bands were imaged using Super-
Signal West Femto Maximum Sensitivity Substrate
(Pierce, USA). The EC3 Imaging System (UVP, USA)
was used to obtained blot images directly from the polyvi-
nylidene difluoride membrane. The quantification of
Western blot data was performed using ImageJ software.
Statistical analysis
Student’s t test or ANOVA test was used where appro-
priate to examine the statistical significance of the dif-
ferences between groups of data. Newman–Keuls tests
were used for post-hoc comparisons when appropriate.
All results are presented as mean ± SE. Significance was
placed at P < 0.05.
Conclusions
Our results indicate that microRNA-301a is neuropro-
tective in oxygen-glucose deprivation-induced neuronal
injury. We provide evidence that glycine is an upstream
regulator of microRNA-301a. We conclude that glycine
confers neuroprotection through microRNA-301a/PTEN
signal pathway.
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